Business Context and Reporting Period
This Form 8-K is a current report filed by Medasorb Technologies Corporation (noting the input metadata references Cytosorbents Corp, but the filing text identifies Medasorb Technologies Corporation) for the reporting period of January 1, 2007. The filing discloses corporate governance changes, specifically the appointment of a new Board Chairman and adjustments to executive compensation.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation and equity awards:
- Chairman Compensation: William R. Miller appointed at $20,000 per annum.
- Equity Grants: 200,000 share option granted at $1.65/share; potential additional 100,000 share option in 2008.
- Executive Salaries (Effective Jan 1, 2006):
- Al Kraus (CEO): $216,351
- David Lamadrid (CFO): $145,801
- Vince Capponi (COO): $195,527
- Bonuses: $200 bonus each to CFO and COO as of December 31, 2006.
Material Changes
The primary material change is the appointment of William R. Miller as Chairman of the Board, effective January 1, 2007. Additionally, the filing confirms salary increases for three executive officers that became effective on January 1, 2006, and the issuance of specific bonuses at the end of 2006.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of personnel changes and compensatory arrangements.
Investor Verification Checklist
- Verify the correct registrant name (Medasorb Technologies Corporation vs. Cytosorbents Corp) to ensure accurate historical tracking.
- Confirm the vesting terms and expiration dates for the 200,000 share option granted to William R. Miller.
- Review the company's capitalization table to assess the dilution impact of the new options.
- Check subsequent filings to confirm if the additional 100,000 share option for 2008 was issued.